Michael Barbella, Managing Editor02.16.23
Perimeter Medical Imaging AI Inc. is touting peer-reviewed research that validates the further exploration of Perimeter’s wide-field Optical Coherence Tomography (WF-OCT) technology in visualizing margins during head and neck surgeries.
The research study—published in JAMA Otolaryngology-Head and Neck Surgery and conducted at Mount Sinai Icahn School of Medicine—included 53 adult patients undergoing primary ablative surgery of the oral cavity or oropharynx for squamous cell carcinoma (SCC). Resected specimens were imaged with Perimeter S-Series OCT in the operating room prior to routine pathology to allow for post-operative comparisons.
“We understand that SCC patients with positive margins after initial surgery are known to have increased risk of local recurrence, poorer rates of progression-free survival, and a need for adjuvant treatments such as radiotherapy, chemotherapy and additional surgery," said Arvind K. Badhey, M.D., Department of Otolaryngology, University of Massachusetts Chan Medical School, and lead author. "Our research findings suggest that wide-field OCT may be a promising adjunct imaging modality for intraoperative visualization in head and neck surgery, especially at deep margins. Our results support the further exploration of Perimeter’s technology, with the hope that this technology could help address this unmet need in SCC patients.”
“Novel technologies that have potential to improve our ability to determine surgical margins are needed in order to improve outcomes in head and neck cancer. This work represents a novel optical coherence imaging approach which has shown promise for examining margin depth in real-time during surgery for tongue cancer, and I am excited to be part of this research effort,” stated Brett A. Miles, DDS M.D., professor and chair, Otolaryngology Head and Neck Surgery, Lenox Hill Hospital, New York, and senior study author.
“This publication further supports the potential use of our flagship Perimeter S-Series OCT medical imaging technology across several tissue types, including head and neck surgery," Perimeter Medical CEO Jeremy Sobotta said. "Further, this clinical research shows that the Perimeter OCT images correlate to histological results, with a process that does not interfere with surgical procedures or final pathology. Ultimately, our hope is that the ‘real-time’ use of our innovative technology can help improve outcomes for patients.”
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI is a medical technology company developing ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the United States, its U.S. Food and Drug Administration-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level, with 10x greater image resolution than X-ray and ultrasound, and 100x greater than MRI. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to $7.4 million awarded by the Cancer Prevention and Research Institute of Texas.
The research study—published in JAMA Otolaryngology-Head and Neck Surgery and conducted at Mount Sinai Icahn School of Medicine—included 53 adult patients undergoing primary ablative surgery of the oral cavity or oropharynx for squamous cell carcinoma (SCC). Resected specimens were imaged with Perimeter S-Series OCT in the operating room prior to routine pathology to allow for post-operative comparisons.
“We understand that SCC patients with positive margins after initial surgery are known to have increased risk of local recurrence, poorer rates of progression-free survival, and a need for adjuvant treatments such as radiotherapy, chemotherapy and additional surgery," said Arvind K. Badhey, M.D., Department of Otolaryngology, University of Massachusetts Chan Medical School, and lead author. "Our research findings suggest that wide-field OCT may be a promising adjunct imaging modality for intraoperative visualization in head and neck surgery, especially at deep margins. Our results support the further exploration of Perimeter’s technology, with the hope that this technology could help address this unmet need in SCC patients.”
“Novel technologies that have potential to improve our ability to determine surgical margins are needed in order to improve outcomes in head and neck cancer. This work represents a novel optical coherence imaging approach which has shown promise for examining margin depth in real-time during surgery for tongue cancer, and I am excited to be part of this research effort,” stated Brett A. Miles, DDS M.D., professor and chair, Otolaryngology Head and Neck Surgery, Lenox Hill Hospital, New York, and senior study author.
“This publication further supports the potential use of our flagship Perimeter S-Series OCT medical imaging technology across several tissue types, including head and neck surgery," Perimeter Medical CEO Jeremy Sobotta said. "Further, this clinical research shows that the Perimeter OCT images correlate to histological results, with a process that does not interfere with surgical procedures or final pathology. Ultimately, our hope is that the ‘real-time’ use of our innovative technology can help improve outcomes for patients.”
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI is a medical technology company developing ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the United States, its U.S. Food and Drug Administration-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level, with 10x greater image resolution than X-ray and ultrasound, and 100x greater than MRI. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to $7.4 million awarded by the Cancer Prevention and Research Institute of Texas.